Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS
source: pixabay.com

FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS

      Science Magazine recently joined other news sources in reporting that Bluebird Bio’s Phase 3 clinical trial investigating a treatment for a neurological disease was put on hold by…

Continue Reading FDA Halted Phase 3 Trial for Cerebral Adrenoleukodystrophy Due to Participant Developing MDS

The MDS Foundation’s Outcomes for High-Risk MDS Patients Undergoing Transplant vs. Standard Non-Transplant Therapies Webinar

  • Post author:
  • Post category:

Outcomes for High-Risk MDS Patients Undergoing Transplant vs. Standard Non-Transplant Therapies August 7, 2021 Speaker: Erica D. Warlick, MD, University of Minnesota Medical Center This free webinar provides an overview…

Continue Reading The MDS Foundation’s Outcomes for High-Risk MDS Patients Undergoing Transplant vs. Standard Non-Transplant Therapies Webinar
Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS
https://unsplash.com/photos/_jbClosDsD4

Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS

In a news release from July 21, 2021, biotechnology company Genentech shared that its therapy Venclexta (venetoclax), in conjunction with azacitidine, received Breakthrough Therapy designation from the FDA. Overall, the…

Continue Reading Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS

The MDS Foundation’s Webcast de MDS en Español

  • Post author:
  • Post category:

Que son los sindromes mielodisplasicos? Guillermo Montalbán Bravo, MD, MD Anderson Cancer Center Este seminario les va a proveer como se determina el diagnóstico de MDS, se estará enfocando en…

Continue Reading The MDS Foundation’s Webcast de MDS en Español

The MDS Foundation’s Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes Webinar

  • Post author:
  • Post category:

Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes April 17, 2021 Speaker: Rami Komrokji, MD; Moffitt Cancer Center Join this webinar to learn the latest about the genetics of myelodysplastic syndromes.…

Continue Reading The MDS Foundation’s Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes Webinar
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors
source: pixabay.com

Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors) are used to treat neoplasms. They are frequently used as a therapy for ovarian cancer. A recent study has attempted to detect the possibility…

Continue Reading Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML

Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…

Continue Reading Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML
50% Enrollment Reached in Imetelstat Trial for MDS
source: pixabay.com

50% Enrollment Reached in Imetelstat Trial for MDS

Since its conception, biopharmaceutical company Geron Corporation ("Geron") has worked to develop first-in-class therapies for hematologic myeloid malignancies. More recently, Geron began evaluating imetelstat for patients with lower risk myelodysplastic syndromes…

Continue Reading 50% Enrollment Reached in Imetelstat Trial for MDS
Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
source: pixabay.com

Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response

According to a story from Hematology Advisor, a recent study released in Scientific Reports indicates that gene expression has the potential to predict both primary resistance and treatment response in patients living…

Continue Reading Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
source: pixabay.com

Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment

Historically, clinical trials have played an immense role in collecting patient data, understanding disease progression, and crafting more targeted treatments. This is especially true in the oncology realm. But according…

Continue Reading Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
source: pixabay.com

September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness

September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…

Continue Reading September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness